Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Jan;73(1):61–64. doi: 10.1136/hrt.73.1.61

Impairment of diastolic function during short-term anthracycline chemotherapy.

Y Cottin 1, C Touzery 1, B Coudert 1, A Gilles 1, P Walker 1, J L Massing 1, M Toubeau 1, A Riedinger-Berriolo 1, D Caillot 1, P Louis 1, et al.
PMCID: PMC483757  PMID: 7888264

Abstract

OBJECTIVE--To assess the early changes in left ventricular diastolic and systolic function due to anthracycline treatment. DESIGN--A prospective study of cardiac function by radionuclide angiography in adults before and one month after the end of anthracycline treatment. PATIENTS--60 patients without cardiac disease treated with chemotherapy containing anthracycline. METHODS--Cardiac function was assessed by radionuclide measurement throughout treatment. Ejection fraction, peak ejection rate, time to peak ejection rate, filling rate, and time to peak filling rate were measured before and after treatment. To normalise radionuclide measurements of the left ventricular diastolic function the ratio of the filling rate to the ejection fraction and the ratio of the filling rate to the peak ejection rate were calculated. RESULTS--No patient developed symptomatic congestive cardiac failure. The ejection fraction decreased from 58% (5%) to 55% (6%) (P < 0.001), the peak ejection rate fell from 2.99 (0.41) to 2.77 (0.41) of the end diastolic volume per second (P < 0.001), and the peak filling rate from 2.71 (0.47) to 2.55 (0.44) of the end diastolic volume per second (P < 0.01) after treatment. No difference was observed in the normalised ratios. CONCLUSIONS--This report shows simultaneous impairment of left ventricular systolic and diastolic radionuclide parameters. The absence of variation in normalised measurements suggests similar changes in ejection fraction, peak ejection rate, and peak filling rate throughout treatment.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J., Dainiak N., Berger H. J., Goldman L., Johnstone D., Reduto L., Duffy T., Schwartz P., Gottschalk A., Zaret B. L. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979 Feb 8;300(6):278–283. doi: 10.1056/NEJM197902083000603. [DOI] [PubMed] [Google Scholar]
  2. Bachur N. R., Gordon S. L., Gee M. V. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res. 1978 Jun;38(6):1745–1750. [PubMed] [Google Scholar]
  3. CROSS C. E., RIEBEN P. A., SALISBURY P. F. Influence of coronary perfusion and myocardial edema on pressure-volume diagram of left ventricle. Am J Physiol. 1961 Jul;201:102–108. doi: 10.1152/ajplegacy.1961.201.1.102. [DOI] [PubMed] [Google Scholar]
  4. Cuocolo A., Sax F. L., Brush J. E., Maron B. J., Bacharach S. L., Bonow R. O. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanisms for systolic dysfunction during exercise. Circulation. 1990 Mar;81(3):978–986. doi: 10.1161/01.cir.81.3.978. [DOI] [PubMed] [Google Scholar]
  5. Dantchev D., Balercia G., Bourut C., Anjo A., Maral R., Mathé G. Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs. Biomed Pharmacother. 1984;38(7):322–328. [PubMed] [Google Scholar]
  6. Janicki J. S., Weber K. T. Factors influencing the diastolic pressure-volume relation of the cardiac ventricles. Fed Proc. 1980 Feb;39(2):133–140. [PubMed] [Google Scholar]
  7. Kusuoka H., Futaki S., Koretsune Y., Kitabatake A., Suga H., Kamada T., Inoue M. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol. 1991 Sep;18(3):437–444. doi: 10.1097/00005344-199109000-00017. [DOI] [PubMed] [Google Scholar]
  8. Lazzarino G., Viola A. R., Mulieri L., Rotilio G., Mavelli I. Prevention by fructose-1,6-bisphosphate of cardiac oxidative damage induced in mice by subchronic doxorubicin treatment. Cancer Res. 1987 Dec 15;47(24 Pt 1):6511–6516. [PubMed] [Google Scholar]
  9. Lee B. H., Goodenday L. S., Muswick G. J., Yasnoff W. A., Leighton R. F., Skeel R. T. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987 Jan;9(1):184–188. doi: 10.1016/s0735-1097(87)80099-2. [DOI] [PubMed] [Google Scholar]
  10. Lee K. J., Southee A. E., Bautovich G. J., Freedman B., McLaughlin A. F., Rossleigh M. A., Hutton B. F., Morris J. G. Normalised radionuclide measures of left ventricular diastolic function. Eur J Nucl Med. 1989;15(3):123–127. doi: 10.1007/BF00254623. [DOI] [PubMed] [Google Scholar]
  11. Lorell B. H., Barry W. H. Effects of verapamil on contraction and relaxation of cultured chick embryo ventricular cells during calcium overload. J Am Coll Cardiol. 1984 Feb;3(2 Pt 1):341–348. doi: 10.1016/s0735-1097(84)80018-2. [DOI] [PubMed] [Google Scholar]
  12. Marchandise B., Schroeder E., Bosly A., Doyen C., Weynants P., Kremer R., Pouleur H. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989 Jul;118(1):92–98. doi: 10.1016/0002-8703(89)90077-x. [DOI] [PubMed] [Google Scholar]
  13. Mortensen S. A., Olsen H. S., Baandrup U. Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J. 1986 Mar;55(3):274–282. doi: 10.1136/hrt.55.3.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Myers C. E., McGuire W. P., Liss R. H., Ifrim I., Grotzinger K., Young R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. doi: 10.1126/science.877547. [DOI] [PubMed] [Google Scholar]
  15. Pelikan P. C., Weisfeldt M. L., Jacobus W. E., Miceli M. V., Bulkley B. H., Gerstenblith G. Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol. 1986 Sep-Oct;8(5):1058–1066. [PubMed] [Google Scholar]
  16. Porta E. A., Joun N. S., Matsumura L., Nakasone B., Sablan H. Acute adriamycin cardiotoxicity in rats. Res Commun Chem Pathol Pharmacol. 1983 Jul;41(1):125–137. [PubMed] [Google Scholar]
  17. Rhoden W., Hasleton P., Brooks N. Anthracyclines and the heart. Br Heart J. 1993 Dec;70(6):499–502. doi: 10.1136/hrt.70.6.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schwartz R. G., McKenzie W. B., Alexander J., Sager P., D'Souza A., Manatunga A., Schwartz P. E., Berger H. J., Setaro J., Surkin L. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun;82(6):1109–1118. doi: 10.1016/0002-9343(87)90212-9. [DOI] [PubMed] [Google Scholar]
  19. Thompson R. C., Canby R. C., Lojeski E. W., Ratner A. V., Fallon J. T., Pohost G. M. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Am Heart J. 1987 Jun;113(6):1444–1449. doi: 10.1016/0002-8703(87)90660-0. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES